OncoTherapy Science, Inc.
4564.T · JPX
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Market Cap | ¥7 | ¥4 | ¥9 | ¥13 |
| - Cash | ¥1 | ¥1 | ¥1 | ¥2 |
| + Debt | ¥0 | ¥0 | ¥0 | ¥0 |
| Enterprise Value | ¥7 | ¥4 | ¥8 | ¥11 |
| Revenue | ¥1 | ¥1 | ¥1 | ¥1 |
| % Growth | 22.9% | -46.2% | -1.6% | – |
| Gross Profit | -¥0 | -¥0 | ¥0 | ¥0 |
| % Margin | -1.7% | -29.1% | 3.7% | 9.9% |
| EBITDA | -¥1 | -¥1 | -¥1 | -¥2 |
| % Margin | -108.2% | -210.7% | -96.1% | -176.6% |
| Net Income | -¥1 | -¥1 | -¥1 | -¥3 |
| % Margin | -108.7% | -211.1% | -98.6% | -222.9% |
| EPS Diluted | -3.12 | -6.05 | -5.81 | -13.72 |
| % Growth | 48.4% | -4.1% | 57.7% | – |
| Operating Cash Flow | -¥1 | -¥1 | -¥1 | -¥2 |
| Capital Expenditures | -¥0 | -¥0 | -¥0 | -¥0 |
| Free Cash Flow | -¥1 | -¥1 | -¥1 | -¥3 |